Daily FNArena News

Sirtex Medical has released data from its SIRFLOX study with some statistically significant outcomes in the treatment of liver cancer.

ResMed has revealed adverse findings from its SERVE-HF trial. While limited to a specific group, brokers concede a lost growth opportunity.

FNArena’s weekly update on short positions in the Australian share market.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Brokers are beginning to believe the worst may be over for mining services company ALS, with upside provided by a focus on Life Sciences.

FNArena provides a weekly update of Australian listed corporate bond issues, current pricing and yield data.

Orica may be in a trough but several brokers hail its ability to respond to cyclical pressures, along with support from the buy-back.

Brokers hail a disciplined approach to spending and with Qantas’ transformation on track, benefits should soon flow to shareholders.

Despite being beset by weak prices recently brokers believe salmon farmer Tassal has a strong long-term growth outlook.

Peter Switzer of the Switzer Super Report outlines why he believes stock markets are still the place to be.

Citi hails Carrapateena and Frieda River projects; few signs of tin recovery; no tailwinds for crude; more supply rationing needed in iron ore.